• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    the present invention discloses compositions and regimes useful in the treatment of phenylketonuria. the compositions include recombinant adeno-associated virus (raav) with a transthyretin enhancer and promoter targeting expression of a human phenylalanine hydroxylase.
    公开号:BR112019013576A2
    申请号:R112019013576
    申请日:2017-12-29
    公开日:2020-02-04
    发明作者:M Wilson James；Agnes SIDRANE Jenny；Ashley Scott
    申请人:Univ Pennsylvania；
    IPC主号:
    专利说明:

    Descriptive Report of the Invention Patent for GENE THERAPY FOR THE TREATMENT OF PHENYL KETONURIA.
    INCORPORATION BY REFERENCE OF THE SUBMITTED MATERIAL IN ELECTRONIC FORMAT [001] The Applicant incorporates by reference the Sequence Listing material deposited in electronic format. This file is called UPN-16-7939PCT_ST25.txt.
    1. INTRODUCTION [002] The application refers to useful modalities for gene therapy for the treatment of phenylketonuria.
    2. FUNDAMENTALS [003] One of the most common inborn errors of metabolism, Phenylketonuria (PKU) occurs in 1 in 10,000 to 15,000 newborns in the United States. Current treatment approaches require that the affected individual consistently follow an unpleasant and expensive dietary restriction and / or take an enzyme replacement with phenylalanine ammonia lyase from birth throughout his life.
    [004] The most common cause of PKU is phenylalanine hydroxylase (PAH) deficiency due to a recessive inheritance mutation in the PAH gene. PAH is mainly expressed in the liver, which catalyzes the irreversible hydroxylation of phenylalanine into tyrosine. Thus, PAH deficiency affects the phenylalanine catabolic pathway, resulting in the accumulation of phenylalanine. High plasma levels of phenylalanine result in the accumulation of phenylalanine in the brain and can affect brain development and function, resulting in intellectual disability and seizures. In addition, the reduction of plasma phenylalanine through dietary restriction and enzyme substitution is expensive, inconvenient and has been associated with several adverse complications, such as persistent mild cognitive deficits.
    Petition 870190072015, of 7/29/2019, p. 6/64
    2/38 [005] An alternative approach to achieve sustained therapeutic levels of PAH is through continuous in vivo production of the native enzyme in hepatocytes using gene transfer mediated by a cell-directed adeno-associated virus (AAV) or other viral vector. viral. Several attempts at expression of vector-mediated PAH have been tested preliminarily in mouse studies. See, for example, Harding et al., Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2 / 8 vector mediated gene therapy in murine phenylketonuria Gene Ther. 2006 Mar; 13 (5): 457-6 and Viecelli et al., Treatment of Phenylketonuria Using Minicircle-Based Naked-DNA Gene Transfer to Murine Liver Hepatology. 2014 Sep; 60 (3): 1035-1043, which are incorporated herein by reference. However, assessments of distribution efficiency, immune stimulation, long-term expression stability and safety are insufficient or not ideal. Thus, more efficient AAV.hPAH vectors are needed for the treatment of PKU. SUMMARY [006] The modalities described in this document refer to an AAV gene therapy vector to deliver normal human phenylalanine hydroxylase (PAH) to a subject in such need, after intravenous administration of the vector resulting in clinically significant long-term correction, maybe 10 years or more, of hyperphenylalaninemia. The patient population in question is that of patients with moderate to severe hyperphenylalaninemia, including those with PKU, PKU variant or non-PKU hyperphenylalaninemia. The target vector dose is intended to deliver blood PAH levels of approximately 15% or more compared to the wild type, which is the level that has been reported for patients with moderate PKU. See, Kaufman, S., PNAS, 96: 3160-4 (1999), which is incorporated into this document by reference. In another modality, the
    Petition 870190072015, of 7/29/2019, p. 7/64
    3/38 target vector dose is intended to deliver PAH to result in a 25% or greater reduction in plasma phenylalanine levels. In one embodiment, the goal for treatment with the AAV vector is the conversion of patients with severe PKU into moderate or mild PKU, thus decreasing the burden associated with a severely limited phenylalanine diet.
    [007] In one aspect, this application provides for the use of a replication deficient adenoassociated virus (AAV) to deliver a human phenylalanine hydroxylase (PAH) gene to liver cells of (human) patients diagnosed with PKU. The recombinant AAV vector (rAAV) used to deliver the hPAH gene (rAAV.hPAH) must have a tropism for the liver (for example, an rAAV carrying an AAV8 capsid), and the hPAH transgene must be controlled by control elements of specific expression of the liver. In one embodiment, the expression control elements include one or more of the following: an intensifier; a promoter; an intron; a WPRE; and a poly A sign. Such elements are further described in this document.
    [008] In one embodiment, the hPAH coding sequence is shown in SEQ ID NO: 1. In one embodiment, the PAH protein sequence is shown in SEQ ID NO: 2. The coding sequence for hPAH is, in a modality, a codon optimized for expression in humans. Such a sequence can share less than 80% identity with the native hPAH coding sequence (SEQ ID NO: 3). In one embodiment, the hPAH coding sequence is shown in SEQ ID NO: 1.
    [009] In another aspect, an aqueous suspension suitable for administration to a patient with PKU that includes the rAAV described in this document is provided in this document. In some embodiments, the suspension includes an aqueous suspension liquid and
    Petition 870190072015, of 7/29/2019, p. 8/64
    4/38 about 1 x 10 12 to about 1 x 10 14 copies of the rAAV / ml genome (GC) / ml. The suspension is, in one embodiment, suitable for intravenous injection. In another embodiment, the suspension also includes a surfactant, preservative and / or buffer dissolved in the aqueous suspension liquid.
    [0010] In another embodiment, a method is provided in this document to treat a patient with PKU with an rAAV as described in this document. In one embodiment, about 1 x 10 11 to about 3 x 10 13 copies of the rAAV genome (GC) / kg of the patient's body weight are distributed to the patient in an aqueous suspension.
    3. BRIEF DESCRIPTION OF THE FIGURES [0011] FIGURE 1 is a schematic representation of the cis plasmid pAAV.TBG.PI.hPAHco.WPRE.bGH.
    [0012] FIGURE 2A is a bar graph of plasma levels of phenylalanine (Phe) in siblings of the same litter as the mouse model PAH_KO_A (shown in white) and wild type (shown in black) or heterozygous (shown in gray) , as described in Example 1. These results are summarized in FIGURE 2D.
    [0013] FIGURE 2B is a line graph of plasma phenylalanine (Phe) levels in PAH_KO_A mice (shown in white) with siblings from the same litter heterozygous (shown in gray) and wild type (shown in black) provided as controls . The mice were injected with 1 x 10 13 GC / kg or 1 x 10 12 GC / kg of AAV8.TBG.PI.hPAHco.WPRE.bGH on day 56 of the natural history study as described in Example 3. The experiment was carried out in 7 males and 3 females of PAH_KO_A mice from the study of natural history.
    [0014] FIGURE 2C is a line graph of plasma phenylalanine (Phe) levels in the injected mouse model PAH_KO_A
    Petition 870190072015, of 7/29/2019, p. 9/64
    5/38 with 1 x 10 13 GC / kg or 1 x 10 12 GC / kg of AAV8.TBG.PI.hPAHco.WPRE.bGH as described in Example 3. Ο day of injection was Day 0.
    [0015] FIGURE 2D is a line graph showing the average Phe levels for the mice studied in FIGURE 2A. Values expressed as mean +/- SEM.
    [0016] FIGURE 3A is a bar graph of the plasma levels of phenylalanine (Phe) in siblings of the mouse model PAH_KO_B (shown in white) and wild type (shown in black) or heterozygous (shown in gray), as described in Example 1. These results are summarized in FIGURE 3D.
    [0017] FIGURE 3B is a line graph of plasma phenylalanine (Phe) levels in PAH_KO_B mice (shown in white) with heterozygous (shown in gray) and wild type (shown in black) littermates provided as controls. The experiment was carried out on 3 female mice PAH_KO_B from the study of natural history.
    [0018] FIGURE 3C is a line graph of plasma phenylalanine (Phe) levels in the mouse model PAH_KO_B injected with 1 x 10 12 GC / kg of AAV8.TBG.PI.hPAHco.WPRE.bGH as described in Example 3 The mice with Identification Numbers 1691, 1695 and 1696 were females injected with 1 x 10 12 GC / kg on day 0.
    [0019] FIGURE 3D is a line graph showing the average Phe levels for the mice studied in FIGURE 3A. Values expressed as mean +/- SEM.
    [0020] FIGURE 4A is a bar graph of plasma levels of phenylalanine (Phe) in siblings of the mouse model PAH_KO_C (shown in white) and wild type (shown in black) or heterozygous (shown in gray), as described
    Petition 870190072015, of 7/29/2019, p. 10/64
    6/38 in Example 1. These results are summarized in FIGURE 4C.
    [0021] FIGURE 4B is a line graph of plasma phenylalanine (Phe) levels in PAH_KO_C mice (shown in white) with heterozygous (shown in gray) and wild type (shown in black) littermates provided as controls. The experiment was carried out on 2 male mice PAH_KO_C from the study of natural history.
    [0022] FIGURE 4C is a line graph showing the mean Phe levels for the mice studied in FIGURE 4A. Values expressed as mean +/- SEM.
    [0023] FIGURE 5 is a bar graph that summarizes the results of FIGs. 2A, 3A and 4A. Plasma levels of phenylalanine (Phe) were detected via LC / MS / MS and data collected from the bleeding of PAH_KO_A, PAH_KO_B and PAH_KO_C mice from 6-8 weeks of age. The plasma was isolated and analyzed for Phe concentration. Wild type litter brothers were provided as negative controls.
    [0024] FIGURES 6A-6C demonstrate that AAV8.TBG.hPAHco rescues phenylalanine levels in PKU_KO_B mice. PKU B mice aged 17-22 weeks received 10 12 GC / kg from one of AAV8.TBG.hPAHco.bGH (circles) or AAV8.TBG.hPAHco.WPRE.bGH (squares) after pre-phenylalanine levels treatment have been established. PBS treatment shown with triangles. The mice were bled weekly and the plasma was isolated and the concentration of phenylalanine was determined (A). At the end of the study, the liver was collected and the analysis of genomic (B) and immunohistochemical (C) copies was performed. Values expressed as mean ± SEM.
    [0025] FIGURE 7 is a line graph showing that AAV gene therapy reduces the plasma Phe concentration in
    Petition 870190072015, of 7/29/2019, p. 11/64
    7/38 PKU_KO_A mice. WT (triangle), heterozygous (circle) and 10 11 GC / kg mice of AAV8.TBG.hPAHco were injected intravenously into PKU_KO_A (KO) mice after baseline phenylalanine levels were established. The mice were then bled weekly and the plasma was isolated and analyzed for Phe concentration. Values expressed as mean +/- SEM. Plasma Phe levels decreased by 71% after intravenous administration of AAV8.TBG.hPAHco.
    [0026] FIGURES 8A-8C demonstrate that a high dose of AAV9.TBG.hPAHco rescues phenylalanine levels in PKU_KO_B mice. The PKU_KO_B mice received 10 12 GC / kg, 3 x 10 11 GC / kg or 10 11 GC / kg of AAV8.TBG.hPAH after the baseline phenylalanine levels had been established. The mice were then bled weekly and the plasma was isolated and analyzed for Phe concentration (A). Values expressed as mean +/- SEM. At the end of the study, the liver was collected and the analysis of genomic (B) and immunohistochemical (C) copies was performed. Protein expression and reduction in Phe levels observed at a dose of 10 12 GC / kg.
    [0027] FIGURE 9 shows an alignment of a portion of the PAH sequence for wild type (WT) (SEQ ID NO: 26), PAH KO A (Strain A) (SEQ ID NO: 27), PAH_KO_B (Strain B) (SEQ ID NO: 28), PAH KO C (strain C) (SEQ ID NO: 29), PAH_KO_D (strain D) (SEQ ID NO: 30) and consensus (SEQ ID NO: 31).
    4. DETAILED DESCRIPTION [0028] The modalities described in the application refer to the use of a replication deficient adenoassociated virus (AAV) to deliver a human phenylalanine hydroxylase (PAH) gene to liver cells of patients (humans) diagnosed with phenylketonuria (PKU ). The recombinant AAV vector (rAAV) used to distribute the hPAH gene (rAAV.hPAH) must have a tropism for the liver (for example, a
    Petition 870190072015, of 7/29/2019, p. 12/64
    8/38 rAAV carrying an AAV8 capsid), and the hPAH transgene must be controlled by control elements of specific liver expression. In one embodiment, the expression control elements include one or more of the following: an intensifier; a promoter; an intron; a WPRE; and a poly A sign. Such elements are further described in this document.
    [0029] As used in this document, AAV8 capsid refers to the AAV8 capsid with the GenBank amino acid sequence, accession number: YP 077180.1, SEQ ID NO: 19, which is incorporated herein by reference. Some variation of this coded sequence is allowed, which may include sequences with about 99% identity to the amino acid sequence referenced in YP_077180.1 and WO 2003/052051 (which is incorporated by reference in this document) (that is, less than 1 % variation of the referenced sequence). Methods for generating capsids, and therefore coding sequences, and methods for producing rAAV viral vectors have been described. See, for example, Gao, et al, Proc. Natl. Acad. Sci. U.S.A. 100 (10), 6081-6086 (2003) and US 2015/0315612.
    [0030] As used in this document, the term NAb titer measures the amount of neutralizing antibodies (eg, anti-AAV NAB) that neutralizes the physiological effect of its target epitope (eg, an AAV). Anti-AAV NAb titers can be measured as described in, for example, Calcedo, R., et al., Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses. Journal of Infectious Diseases, 2009. 199 (3): p. 381-390, which is incorporated herein by reference.
    [0031] The terms percentage (%) of identity, sequence identity, percentage of sequence identity or identical percentage in the context of amino acid sequences refer to residues in the two sequences that are the same when
    Petition 870190072015, of 7/29/2019, p. 13/64
    9/38 aligned for correspondence. The percent identity can be readily determined for amino acid sequences over the entire length of a protein, polypeptide, about 32 amino acids, about 330 amino acids, or a peptide fragment thereof or the corresponding nucleic acid sequence coding sequencers . A suitable amino acid fragment can be at least about 8 amino acids in length and can be up to about 700 amino acids. Generally, when referring to the identity, homology or similarity between two different sequences, the identity, homology or similarity is determined in reference to aligned sequences. Aligned sequences or alignments refer to multiple nucleic acid sequences or protein sequences (amino acids), often containing corrections for missing or additional bases or amino acids compared to a reference sequence. Alignments are performed using any of the multiple publicly or commercially available Multi-String Alignment Programs. Sequence alignment programs are available for amino acid sequences, for example, the Clustal X, MAP, PIMA, MSA, BLOCKMAKER, MEME and Match-Box programs. Generally, any of these programs are used in the default settings, although one skilled in the art can change these settings as needed. Alternatively, one skilled in the art can use another algorithm or computer program that provides at least the same level of identity or alignment as that provided by the referenced algorithms and programs. See, for example, J.D. Thomson et al, Nucl. Acids. Res., A comprehensive comparison of multiple sequence alignments, 27 (13): 2682-2690 (1999).
    [0032] As used in this document, the term
    Petition 870190072015, of 7/29/2019, p. 14/64
    10/38 operationally linked refers to the expression control sequences that are contiguous to the gene of interest and the expression control sequences that act in trans or at a distance to control the gene of interest.
    [0033] A virus with defective replication or viral vector refers to a synthetic or artificial viral particle in which an expression cassette containing a gene of interest is packaged in a capsid or viral envelope, where any viral genomic sequence is also packaged within the capsid viral or envelope are deficient in replication; that is, they cannot generate progeny virions, but retain the ability to infect target cells. In one embodiment, the viral vector's genome does not include genes that encode the enzymes needed to replicate (the genome can be designed to be gutless - containing only the transgene of interest flanked by the signals needed for amplification and packaging of the artificial genome), but these genes can be supplied during production. Therefore, it is considered safe for use in gene therapy, since replication and infection by progeny virions cannot occur, except in the presence of the viral enzyme necessary for replication.
    [0034] It should be noted that the term one or one refers to one or more. Accordingly, the terms one (or one), one or more and at least one are used interchangeably in this document.
    [0035] The words understand, understand and understand must be interpreted inclusive instead of exclusively. The words consist, consist and their variants must be interpreted exclusively, and not inclusive. Although several modalities in the specification are presented using language comprising, in other circumstances, a related modality is also intended to be interpreted and described
    Petition 870190072015, of 7/29/2019, p. 15/64
    11/38 using language consisting of or consisting essentially of.
    [0036] As used in this document, the term about means a 10% variability in relation to the given reference, unless otherwise specified.
    [0037] Unless otherwise defined in this specification, the technical and scientific terms used in this document have the same meaning as that understood in the art and by reference to published texts that provide those skilled in the art with general guidance for several of the terms used in this application .
    5.1 Gene Therapy Vectors [0038] In one aspect, a recombinant adenoassociated virus (rAAV) vector carrying the human PAH gene is provided for use in gene therapy. The vector rAAV.hPAH must have a tropism for the liver (for example, a rAAV carrying an AAV8 capsid) and the hPAH transgene must be controlled by liver-specific expression control elements. The vector is formulated in a buffer / carrier suitable for infusion in human subjects. The plug / carrier should include a component that prevents the rAAV from sticking to the infusion tubing, but does not interfere with the in vivo binding activity to the rAAV.
    5.1.1. The vector rAAV.hPAH
    5.1.1.1. The sequence hPAH [0039] Phenylketonuria is a hereditary error in metabolism caused predominantly by mutations in the phenylalanine hydroxylase (PAH) gene. Mutations in the PAH gene result in decreased catalytic activity affecting the catabolic pathway of phenylalanine (Phe). PAH is a liver enzyme that requires the tetrahydrobiopterin cofactor (BH4) to convert Phe to tyrosine (Tyr). A deficiency in PAH or its BH4 cofactor results in the accumulation of excess phenylalanine,
    Petition 870190072015, of 7/29/2019, p. 16/64
    12/38 whose toxic effects can cause severe and irreversible intellectual disability and other disorders, if not treated. See, Havid and Cristodoulou, Transi Pediatr, 2015 Oct, 4 (4): 304-17, which is incorporated into this document by reference.
    [0040] Over 550 PAH gene mutations have been described, most of which result in deficient enzyme activity. See, Phenylalanine Hydroxylase Locus Knowledgebase, accessed at http://www.pahdb.mcgill.ca/, which is incorporated into this document by reference. Due to the large number of known PKU mutations and the autosomal recessive nature of the disease, a wide range of disease severity is observed. The severity of the disease is usually classified by the levels of phenylalanine in the blood, which are sometimes classified as classic PKU, moderate or variant PKU, mild PKU or hyperphenylalaninemia. Based on blood levels of Phe at the time of diagnosis, there are 4 levels of severity of PKU.
    [0041] · Hyperphenylalaninemia, with Phe levels slightly above the normal range: 120-600 pmol / L (2-10 mg / dL) [0042] · Mild, with the lowest levels of Phe in the blood: 600900 pmol / L (10-15 mg / dL) [0043] · Moderate or variant, with blood levels of Phe in an intermediate position: 900-1200 pmol / L (15-20 mg / dL) [0044] · Severe or classical PKU, with extremely high blood levels of Phe:> 1200 pmol / L (20 mg / dL) [0045] The goal of therapies described in this document would provide a functional PAH enzyme resulting in Phe levels in the range of 120-600 pmol / L, for example , a 25% or more reduction in plasma Phe levels. In another embodiment, the desired vector dose is intended to deliver PAH in order to result in a 25% or more reduction in plasma phenylalanine levels. In another embodiment, the desired vector dose is intended to distribute PAH in order to
    Petition 870190072015, of 7/29/2019, p. 17/64
    13/38 result in a reduction of plasma phenylalanine levels by 30% or more. In another embodiment, the desired vector dose is intended to deliver PAH in order to result in a 35% or greater reduction in plasma phenylalanine levels. In another embodiment, the desired vector dose is intended to deliver PAH in order to result in a 40% or greater reduction in plasma phenylalanine levels. In another embodiment, the desired vector dose is intended to deliver PAH in order to result in a 45% or greater reduction in plasma phenylalanine levels. In another embodiment, the desired vector dose is intended to deliver PAH in order to result in a 50% or more reduction in plasma phenylalanine levels. In another embodiment, the desired vector dose is intended to deliver PAH in order to result in a 60% or greater reduction in plasma phenylalanine levels. In another embodiment, the desired vector dose is intended to deliver PAH in order to result in a reduction of plasma phenylalanine levels by 70% or more. In another embodiment, the desired vector dose is intended to deliver PAH in order to result in a reduction of plasma phenylalanine levels by 75% or more. [0046] In one embodiment, the subject or patient is a mammalian subject with PKU as described above. It is intended that a patient with PKU of any severity is the intended subject.
    [0047] In one embodiment, the hPAH gene encodes the hPAH protein shown in SEQ ID NO: 2. Thus, in one embodiment, the hPAH transgene may include, but is not limited to, the sequence provided by SEQ ID NO: 1 or SEQ ID NO: 3 which are provided in the attached Sequence Listing, which is incorporated herein by reference. SEQ ID NO: 3 provides the cDNA for native human PAH. SEQ ID NO: 1 provides a engineered cDNA for human PAH, which has been encoded for expression in humans (sometimes referred to herein as hPAHco). It should be understood that the reference to hPAH
    Petition 870190072015, of 7/29/2019, p. 18/64
    14/38 in this document may, in some modalities, refer to the native or codon-optimized sequence of hPAH. Alternatively or in addition, web-based or commercially available computer programs, as well as specialized service companies can be used to back-translate amino acid sequences into nucleic acid coding sequences, including RNA and / or cDNA. See, for example, backtranseq by EMBOSS, http://www.ebi.ac.uk/Tools/st/; Gene Infinity (http://www.geneinfinity.org/sms-/sms_backtranslation.html); ExPasy (http://www.expasy.org/tools/). All nucleic acids encoding the described hPAH polypeptide sequences are intended to be encompassed, including nucleic acid sequences that have been optimized for expression in the desired target subject (for example, by codon optimization).
    [0048] In one embodiment, the hPAH-encoding nucleic acid sequence shares at least 95% identity with the native hPAH-encoding sequence of SEQ ID NO: 3. In another embodiment, the hPAH-encoding nucleic acid sequence shares at least 90, 85, 80, 75, 70 or 65% identity with the native hPAH coding sequence of SEQ ID NO: 3. In one embodiment, the nucleic acid sequence encoding hPAH shares about 78% identity with the sequence of native hPAH coding of SEQ ID NO: 3. In one embodiment, the nucleic acid sequence encoding hPAH is SEQ ID NO: 1.
    [0049] In one embodiment, the PAH coding sequence is optimized for expression in the target subject. Codon-optimized coding regions can be designed by several different methods. This optimization can be carried out using methods that are available online (for example, GeneArt), published methods or a company that provides coding optimization services, for example
    Petition 870190072015, of 7/29/2019, p. 19/64
    15/38 example, such as DNA2.0 (Menlo Park, CA). A codon optimization approach is described, for example, in International Patent Publication No. WO 2015/012924, which is incorporated herein by reference. See also, for example, US patent publication 2014/0032186 and US patent publication 2006/0136184. Suitably, the total length of the open reading frame (ORF) for the product is modified. However, in some modalities, only a fragment of the ORF can be changed. Using one of these methods, frequencies can be applied to any polypeptide sequence and produce a nucleic acid fragment from a codon-optimized coding region encoding the polypeptide.
    [0050] Several options are available to make the actual codon changes or to synthesize codon-optimized coding regions designed as described here. Such modifications or synthesis can be carried out using standard and routine molecular biological manipulations well known to those skilled in the art. In one approach, a series of complementary oligonucleotide pairs of 80-90 nucleotides each in length and spanning the length of the desired sequence are synthesized using standard methods. These pairs of oligonucleotides are synthesized in such a way that after pairing, they form double-stranded fragments of 80-90 base pairs, containing cohesive ends, for example, each oligonucleotide in the pair is synthesized to extend 3, 4, 5, 6 , 7, 8, 9 10, or more bases in addition to the region that is complementary to the other oligonucleotide in par. The single-stranded ends of each oligonucleotide pair are designed to pair with the single-stranded end of another oligonucleotide pair. Oligonucleotide pairs are allowed to pair, and approximately five to six of these
    Petition 870190072015, of 7/29/2019, p. 20/64
    16/38 double-stranded fragments are then allowed to pair together through the single-stranded cohesive ends, and then are linked and cloned into a standard bacterial cloning vector, for example, The TOPO® vector is available from Thermo Fisher Scientific Inc. construct is then sequenced by standard methods. Several of these constructs consisting of 5 to 6 fragments of fragments of 80 to 90 base pairs linked together, that is, fragments of about 500 base pairs, are prepared in such a way that the entire desired sequence is represented in a series of plasmatic constructs. The inserts of these plasmids are then cut with appropriate restriction enzymes and linked together to form the final construct. The final construct is then cloned into a standard bacterial cloning vector and sequenced. Additional methods would be immediately apparent to the person skilled in the art. In addition, genetic synthesis is readily available commercially.
    5.1.1.2. The rAAV vector [0051] As PAH is expressed natively in the liver, it is desirable to use an AAV that shows tropism for the liver. In one embodiment, the AAV that provides the capsid is AAV8. In another modality, the AAV that provides the capsid is AAVrh.10. In yet another modality, the AAV that supplies the capsid is an EIA Ciado E. Such AAV includes rh.2; rh. 10; rh. 25; bb.1, bb.2, pi. 1, pi.2, pi.3, rh.38, rh.40, rh.43, rh.49, rh.50, rh.51, rh.52, rh.53, rh.57, rh.58, rh.61, rh.64, hu.6, hu.17, hu.37, hu.39, hu.40, hu.41, hu.42, hu.66 and hu.67. This data also includes modified rh. 2; modified rh. 58; and modified rh.64. See, WO 2005/033321, which is incorporated herein by reference. However, any one of a number of rAAV vectors with tropism for the liver can be used.
    [0052] In a specific modality described in the Examples, below, the gene therapy vector is an AAV8 vector that expresses a transgene
    Petition 870190072015, of 7/29/2019, p. 21/64
    17/38 hPAH under the control of a thyroxine-binding globulin (TBG) promoter referred to as AAV8.TBG.PI.hPAHco.WPRE.bGH. The genome of the vector for such a vector is shown in SEQ ID NO: 20. In another embodiment, the WPRE is omitted, that is, AAV8.TBG.PI.hPAHco.bGH. The vector genome for such a vector is shown in SEQ ID NO: 21. The external component of the AAV vector is an icosahedral capsid of serotype 8, T = 1, consisting of 60 copies of three AAV viral proteins, VP1, VP2 and VP3 , in a 1: 1: 10 ratio. The capsid contains a single stranded DNA rAAV vector genome.
    [0053] In one embodiment, the rAAV.hPAH genome contains an hPAH transgene flanked by two inverted AAV terminal repeats (ITRs). In one embodiment, the hPAH transgene includes one or more of an enhancer, promoter, an intron, a Post-Transcriptional Regulatory Element for Groundhog Hepatitis Virus (WHP) (WPRE) (for example, SEQ ID NO: 15), a hPAH coding sequence and polyadenylation signal (poly A). In another embodiment, the hPAH transgene includes one or more of an enhancer, promoter, an intron, an hPAH coding sequence and a polyadenylation signal (poly A). These control sequences are operably linked to the hPAH gene sequences. The expression cassette containing these sequences can be manipulated into a plasmid that is used to produce a viral vector.
    [0054] ITRs are the genetic elements responsible for the replication and packaging of the genome during vector production and are the only cis viral elements required to generate rAAV. The minimum sequences required to package the expression cassette into an AAV viral particle are AAV 5 'and 3' ITR, which may be of the same AAV origin as the capsid, or of a different AAV origin (to produce an AAV pseudotype). In one mode, the AAV2 ITR sequences are used, or the deleted version of the same
    Petition 870190072015, of 7/29/2019, p. 22/64
    18/38 (AITR). However, ITRs from other AAV sources can be selected. When the source of the ITRs is from AAV2 and the AAV capsid is from another source of AAV, the resulting vector can be called pseudotyped. Typically, an expression cassette for an AAV vector comprises an AAV 5 'ITR, hPAH coding sequences and any regulatory sequences, and an AAV 3' ITR. However, other configurations of these elements may be appropriate. An abbreviated version of the 5 'ITR, called AITR, has been described, in which the terminal resolution site (trs) and the D sequence are excluded. In other embodiments, full AAV 5 'and 3' ITRs are used. In one embodiment, ITR 5 'is that shown in SEQ ID NO: 16. In one embodiment, ITR 3' is that shown in SEQ ID NO: 17.
    [0055] In one embodiment, the expression control sequences include one or more enhancers. In one embodiment, the En34 enhancer is included (enhancer of the 34 bp nucleus of the human apolipoprotein liver control region), which is presented in SEQ ID NO: 4. In another embodiment, the EnTTR (100 bp transthyretin enhancer sequence) it's included. Such a sequence is shown in SEQ ID NO: 5. See, Wu et al., Molecular Therapy, 16 (2): 280-289, Feb. 2008, which is incorporated into this document by reference. In yet another modality, the precursor a1microglogulin / bicunin enhancer is included. In yet another modality, ABPS (abbreviated version of the distal enhancer of 100 bp from the precursor enhancer of a1-microglogulin / bicunin [ABP] to 42 bp) is included. Such a sequence is shown in SEQ ID NO: 6. In yet another modality, the ApoE enhancer is included. Such a sequence is shown in SEQ ID NO: 7. In another embodiment, more than one enhancer is present. Such a combination may include more than one copy of any of the enhancers described in this document and / or more than one type of enhancer.
    Petition 870190072015, of 7/29/2019, p. 23/64
    19/38 [0056] The expression of the hPAH coding sequence is driven from a specific liver promoter. An illustrative plasmid and vector described in this document use the thyroxine-binding globulin (TBG) promoter (SEQ ID NO: 9), or a modified version thereof. A modified version of the TBG promoter is an abbreviated version, called TBG-S1. A modified thyroxine-binding globulin (TBG-S1) promoter sequence is shown in SEQ ID NO: 8. Alternatively, other liver-specific promoters, such as the transthyretin promoter, can be used. Another suitable promoter is alpha 1 antitrypsin (A1 AT), or a modified version of it (the sequence of which is shown in SEQ ID NO: 10). Another suitable promoter is the TTR promoter (SEQ ID NO: 11). Other suitable promoters include human albumin (Miyatake et al., J. Virol, 71: 5124 32 (1997)), humAlb; the Liver-specific Promoter (LSP) and hepatitis B virus nucleus promoter, (Sandig et al, Gene Ther., 3: 1002 9 (1996). See, for example, the database of the gene-specific promoter liver, Cold Spring Harbor, http://rulai.schl.edu/LSPD, which is incorporated by reference, although less desired, other promoters, such as viral promoters, constitutive promoters, regulated promoters [see, for example, WO 2011 / 126808 and WO 2013/04943], or a promoter responsive to physiological stimuli can be used in the vectors described in this document.
    [0057] In addition to a promoter, an expression cassette and / or a vector may contain other suitable initiation, termination, and transcription enhancer sequences, as well as efficient RNA processing signals. Such sequences include junction and polyadenylation (poly A) signals; regulatory elements that increase expression (ie, WPRE (SEQ ID NO: 15)); sequences that stabilize cytoplasmic mRNA; sequences that improve the
    Petition 870190072015, of 7/29/2019, p. 24/64
    20/38 translation efficiency (that is, a Kozak consensus sequence); sequences that increase protein stability; and, when desired, sequences that increase the secretion of the encoded product. In one embodiment, a polyadenylation signal (polyA) is included to mediate the termination of hPAH mRNA transcripts. Examples of other suitable poly A sequences include, for example, bovine growth hormone (SEQ ID NO: 12), SV40, rabbit beta-globin and TK poly A, among others.
    [0058] In one embodiment, regulatory sequences are selected in such a way that the genome of the total rAAV vector is about 2.0 to about 5.5 kilobases in size. In one embodiment, regulatory sequences are selected so that the genome of the total rAAV vector is about 3.4 kb, about 2.9 kb, about 3.3 kb, about 2.2 kb or about 2.5 kb in size. In one embodiment, it is desirable that the genome of the rAAV vector approximate the size of the native AAV genome. Thus, in one embodiment, regulatory sequences are selected in such a way that the total genome of the rAAV vector is about 4.7 kb in size. In another embodiment, the total genome of the rAAV vector is less than 5.2 kb in size. The size of the vector's genome can be manipulated based on the size of the regulatory sequences, including the promoter, enhancer, intron, poly A, etc. See, Wu et al, Mol Ther, Jan 2010 18 (1): 80-6, which is incorporated into this document by reference.
    [0059] Thus, in one mode, an intron is included in the vector. Suitable introns include human beta globin IVS2 (SEQ ID NO: 13). See, Kelly et al, Nucleic Acids Research, 43 (9): 4721-32 (2015), which is incorporated into this document by reference. Another suitable promoter includes the chimeric intron of Promega (SEQ ID NO: 14), sometimes referred to as PI). See, Almond, B. and Schenborn, E. T. A Comparison of pCI-neo Vector and pcDNA4 / HisMax Vector. [Internet]
    Petition 870190072015, of 7/29/2019, p. 25/64
    21/38
    2000, which is incorporated into this document by reference. Available at: www.promega.com/resources/pubhub/enotes/a-comparison-of- pcineo-vector-and-pcdna4hismax-vector /). Another suitable intron includes the hFIX intron (SEQ ID NO: 18). Several suitable introns in this document are known in the art and include, without limitation, those found at http://bpg.utoledo.edu/~afedorov/lab/eid.html, which is incorporated into this document by reference. See also, Shepelev V., Fedorov A. Advances in the Exon-Intron Database. Briefings in Bioinformatics 2006, 7: 178-185, which is incorporated into this document by reference.
    [0060] In one embodiment, the genome of the rAAV vector comprises SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24 or SEQ ID NO: 25.
    5.1.2. Compositions [0061] In one embodiment, the rAAV.hPAH virus is supplied in a pharmaceutical composition that comprises a carrier, excipient, diluent or aqueous buffer. In one embodiment, the buffer is PBS. In a specific embodiment, the rAAV.hPAH formulation is a suspension containing an effective amount of rAAV.hPAH vector suspended in an aqueous solution containing 0.001% Pluronic F-68 in TMN200 (200 mM sodium chloride, 1 mM magnesium chloride, 20 mM Tris, pH 8.0). However, several suitable solutions are known including those that include one or more of: buffering saline, a surfactant and a physiologically compatible salt or mixture of salts adjusted to an ionic strength equivalent to about 100 mM sodium chloride (NaCI) to about 250 mM sodium chloride or a physiologically compatible salt adjusted to an equivalent ion concentration.
    [0062] For example, a suspension as provided herein may contain both NaCI and KCI. The pH can be in the range of 6.5 to 8.5
    Petition 870190072015, of 7/29/2019, p. 26/64
    22/38 or 7 to 8.5 or 7.5 to 8. A suitable surfactant, or combination of surfactants, can be selected from Poloxamers, that is, non-ionic triblock copolymers composed of a central hydrophobic polyoxypropylene chain (polypropylene oxide ) flanked by two hydrophilic polyoxyethylene (polyethylene oxide) chains, SOLUTOL HS 15 (Macrogol-15 hydroxystearate), LABRASOL (polyoxyacrylic glyceride), polyoxy-10 oleic ether, TWEEN (polyoxyethylene fatty acid esters) , ethanol and polyethylene glycol. In one embodiment, the formulation contains a poloxamer. These copolymers are usually named with the letter P (of poloxamer) followed by three digits: the first two digits x 100 give the approximate molecular mass of the polyoxypropylene core and the last digit x 10 indicates the percentage of polyoxyethylene. In one mode, the Poloxamer 188 is selected. The surfactant can be present in an amount of about 0.0005% to about 0.001% of the suspension. In another embodiment, the vector is suspended in an aqueous solution containing 180 mM sodium chloride, 10 mM sodium phosphate, 0.001% Poloxamer 188, pH 7.3.
    [0063] In one embodiment, the formulation is suitable for use in human subjects and is administered intravenously. In one embodiment, the formulation is administered through a peripheral vein by bolus injection. In one embodiment, the formulation is administered through a peripheral vein by infusion over about 10 minutes (± 5 minutes). In one embodiment, the formulation is administered through a peripheral vein by infusion over about 20 minutes (± 5 minutes). In one embodiment, the formulation is administered through a peripheral vein by infusion over about 30 minutes (± 5 minutes). In one embodiment, the formulation is administered through a peripheral vein by infusion over about 60 minutes (± 5 minutes). In one embodiment, the formulation is
    Petition 870190072015, of 7/29/2019, p. 27/64
    23/38 administered through a peripheral vein by infusion over approximately 90 minutes (± 10 minutes). However, this time can be adjusted as needed or desired. Any suitable method or route can be used to administer a composition containing AAV as described in this document and, optionally, to co-administer other drugs or active therapies in conjunction with the AAV-mediated distribution of hPAH described herein. Routes of administration include, for example, the systemic, oral, inhalation, intranasal, intratracheal, intraarterial, intraocular, intravenous, intramuscular, subcutaneous, intradermal routes and other parental routes of administration.
    [0064] In one embodiment, the formulation may contain, for example, from about 1.0 x 10 11 copies of the genome per kilogram of the patient's body weight (GC / kg) to about 1 x 10 15 GC / kg, about 5 x 10 11 copies of the genome per kilogram of the patient's body weight (GC / kg) at about 3 x 10 13 GC / kg, or from about 1 x 10 12 to about 1 x 10 14 GC / kg , as measured by oqPCR by digital droplet PCR (ddPCR) as described in, for example, M. Lock et al., Hum Gene Ther Methods. April 2014; 25 (2): 115-25. doi: 10,1089 / hgtb.2013.131. Epub February 14, 2014, which is incorporated into this document by reference. In one embodiment, the formulation rAAV.hPAH is a suspension containing at least 1 x 10 13 copies of the genome (GC) / mL, or higher, as measured by oqPCR or digital drop PCR (ddPCR) as described in, for example, M. Lock et al., Supra.
    [0065] To ensure that empty capsids are removed from the dose of AAV.hPAH that is administered to patients, empty capsids are separated from the vector particles during the vector purification process, for example, using the method discussed in this document. In one embodiment, vector particles containing packaged genomes are purified from empty capsids
    Petition 870190072015, of 7/29/2019, p. 28/64
    24/38 using the process described in US Patent Application No. 62 / 322,098, filed April 13, 2016 and entitled Scalable Purification Method for AAV8, which is incorporated by reference in this document. Briefly, a two-step purification scheme is described that selectively captures and isolates the genome-containing rAAV vector particles from the concentrated, clarified supernatant of a rAAV-producing cell culture. The process uses an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at a high pH to provide rAAV vector particles that are substantially free of rAAV intermediates. Similar purification methods can be used for vectors with other capsids.
    [0066] Although any conventional manufacturing process can be used, the process described in this document (and in US Patent Application No. 62 / 322,098) produces vector preparations in which between 50 and 70% of the particles have a vector genome , that is, 50 to 70% of complete particles. Thus, for an exemplary dose of 1.6 x 10 12 GC / kg, the total particle dose will be between 2.3 x 10 12 and 3 x 10 12 particles. In another embodiment, the proposed dose is a higher log medium, or 5 x 10 12 GC / kg, and the total particle dose will be between 7.6 x 10 12 and 1.1 x 10 13 particles. In one embodiment, the formulation is defined by a stock of rAAV with a void-to-filled ratio of 1 or less, preferably less than 0.75, more preferably 0.5, preferably less than 0.3.
    [0067] A stock or preparation of rAAV8 particles (packaged genomes) is substantially free of empty AAV capsids (and other intermediates) when the rAAV8 particles in the stock are at least about 75% to about 100%, at least about 80%, at least about 85%, at least about 90%, at least about
    Petition 870190072015, of 7/29/2019, p. 29/64
    25/38 of 95%, or at least 99% of rAAV8 in stock and empty capsids are less than about 1%, less than about 5%, less than about 10%, less than about 15% of rAAV8 in stock or preparation.
    [0068] Generally, methods for evaluating empty capsids and AAV vector particles with packaged genomes are known in the art. See, for example, Grimm et al., Gene Therapy (1999) 6: 1322-1330; Sommer et al., Molec. The R. (2003) 7: 122-128. To test the denatured capsid, methods include subjecting the treated AAV stock to SDS polyacrylamide gel electrophoresis, consisting of any gel capable of separating the three capsid proteins, for example, a gel gradient containing 3-8% Trisacetate in the buffer, then drain the gel until the sample material is separated and transfer the gel to nylon or nitrocellulose membranes, preferably nylon. AAV anticapsid antibodies are then used as primary antibodies that bind to denatured capsid proteins, preferably an AAV anticapsid monoclonal antibody, more preferably the anti-AAV-2 B1 monoclonal antibody (Wobus et al., J Virol. (2000) 74: 9281-9293). Then, a secondary antibody is used, one that binds to the primary antibody and contains a means to detect binding to the primary antibody, more preferably an anti-IgG antibody containing a detection molecule covalently linked to it, more preferably an IgG antibody sheep anti-mouse covalently linked to horseradish peroxidase. A method for detecting binding is used to semi-quantitatively determine the binding between the primary and secondary antibodies, preferably a detection method capable of detecting radioactive isotope emissions, electromagnetic radiation or colorimetric changes, more preferably a chemiluminescence detection kit. For example, for SDS
    Petition 870190072015, of 7/29/2019, p. 30/64
    26/38
    PAGE, samples of column fractions can be taken and heated in SDS-PAGE loading buffer containing a reducing agent (eg, DTT) and the capsid proteins were resolved into polyacylamide gels with a pre-fused gradient (eg, Novex). Silver staining can be performed using SilverXpress (invitrogen, CA) according to the manufacturer's instructions, in one embodiment, the concentration of AAV vector genomes (vg) in column fractions can be measured by quantitative PCR in real time ( Q ~ PGR). The samples are diluted and digested with DNase I (or another suitable nuclease) to remove exogenous DNA. After deactivating the nuclease, the samples are further diluted and amplified using primers and a TaqMan ™ Anorogenic probe specific for the DNA sequence between the primers. The number of cycles required to achieve a defined level of fluorescence (limit cycle, Ct) is measured for each sample in an Applied Biosystems Prism 7700 Sequence Detection System. A plasmid DNA containing sequences identical to those contained in the AAV vector is used to generate a standard curve in the Q-PCR reaction. The cycle threshold (Ct) values obtained from the samples are used to determine the vector genome titer by normalizing it to the Ct value of the plasmid standard curve. Parameter tests based on digital PCR can also be used.
    [0069] In one aspect, an optimized q-PCR method is provided in this document that uses a broad spectrum serine protease, for example, proteinase K (as commercially available from Qiagen). More particularly, the optimized qPCR genome titer assay is similar to a standard assay, except that after digestion with DNase I the samples are diluted with proteinase K buffer and treated with proteinase K followed by thermal deactivation. Suitable samples are diluted with buffer
    Petition 870190072015, of 7/29/2019, p. 31/64
    27/38 proteinase K in an amount equal to the sample size. The proteinase K buffer can be concentrated 2 times or more. In general, proteinase K treatment is about 0.2 mg / ml, but can vary between 0.1 mg / ml and about 1 mg / ml. The treatment step is usually conducted at about 55Ό for about 15 minutes, but can be performed at a lower temperature (for example, about 37Ό to about 50Ό) for a longer period of time (for example, about 20 minutes to about 30 minutes) or at a higher temperature (for example, up to about 60Ό) for a shorter period of time (for example, about 5 to 10 minutes). Similarly, deactivation generally takes place at about 95Ό for about 15 minutes, but the temperature can be lowered (for example, about 70Ό to about 90Ό) and the time extended (for example, about 20 minutes to about 30 minutes). The samples are then diluted (for example, 1000 times) and subjected to a TaqMan analysis, as described in the standard assay.
    [0070] In addition, or alternatively, digital drip PCR (ddPCR) can be used. For example, methods for determining self-complementary and single-strand AAV vector genome titers have been described by ddPCR. See, for example, M. Lock et al, Hu Gene Therapy Methods, Hum Gene Ther Methods. April 2014; 25 (2): 11525. doi: 10,1089 / hgtb.2013.131. Epub February 14, 2014.
    5.2 Patient Population [0071] As discussed above, a subject with PKU of any severity is the intended recipient of the compositions and methods described in this document.
    [0072] Subjects may be allowed to continue their standard treatment (for example, low Phe diet; treatment with sapropterin dihydrochloride) before and simultaneously with gene therapy treatment, at the discretion of their responsible physician.
    Petition 870190072015, of 7/29/2019, p. 32/64
    28/38
    Alternatively, the physician may prefer to stop the standard therapies before administering the gene therapy treatment and, optionally, resume the standard treatments such as co-therapy after the administration of the gene therapy.
    [0073] The desirable parameters of the gene therapy regimen are an increase in PAH activity resulting in Phe levels between 120-360 pmol / L. In another embodiment, the vector dose is intended to deliver PAH in order to result in a reduction of plasma phenylalanine levels by 25% or more. In another embodiment, the desirable parameter is to reduce the levels of Phe in the plasma to bring the subject from a severe phenotype to a moderate phenotype. Methods for measuring phenylalanine levels are known in the art, for example, as described in Gregory et al, Blood phenylalanine monitoring for dietary compliance among patients with phenylketonuria: comparison of methods, Genetics in Medicine (November 2007) 9, 761- 765, which is incorporated into this document by reference. In one embodiment, patients achieve desired levels of circulating PAH after treatment with rAAV.hPAH, alone and / or combined with the use of adjuvant treatments.
    5.3. Dosage & Route of Administration [0074] In one embodiment, the vector rAAV.hPAH is administered as a single dose per patient. In one embodiment, the subject receives the minimum effective dose (MED) (as determined by the preclinical study described in the Examples in this document). As used in this document, MED refers to the dose of rAAV.hPAH required to achieve PAH activity resulting in Phe levels between 120-360 pmol / L.
    [0075] As is conventional, the vector title is determined based on the DNA content of the vector preparation. In one embodiment, quantitative PCR or optimized quantitative PCR, as described in
    Petition 870190072015, of 7/29/2019, p. 33/64
    29/38
    Examples, it is used to determine the DNA content of the rAAV.hPAH vector preparations. In one embodiment, digital droplet PCR, as described above, is used to determine the DNA content of the rAAV.hPAH vector preparations. In one embodiment, the dosage is from about 1 x 10 11 copies of the genome (GC) / kg of body weight to about 1 x 10 13 GC / kg, including the parameters. In one embodiment, the dosage is 5 x 10 11 GC / kg. In another embodiment, the dosage is 5 x 10 12 GC / kg. In specific modalities, the dose of rAAV.hPAH administered to the patient is at least 5 x 10 11 GC / kg, 1 x 10 12 GC / kg, 1.5 x 10 12 GC / kg, 2.0 x 10 12 GC / kg, 2.5 x 10 12 GC / kg, 3.0 x 10 12 GC / kg, 3.5 x 10 12 GC / kg, 4.0 x 10 12 GC / kg, 4.5 x 10 12 GC / kg, 5.0 x 10 12 GC / kg, 5.5 x 10 12 GC / kg, 6.0 x 10 12 GC / kg, 6.5 x 10 12 GC / kg, 7.0 x 10 12 GC / kg, or 7.5 x 10 12 GC / kg. In addition, replicated defective virus compositions can be formulated in dosage units to contain an amount of replicated defective virus in the range of about 1.0 x 10 9 GC to about 1.0 x 10 15 GC. As used herein, the term dosage may refer to the total dosage administered to the subject during treatment, or the amount administered in a single (or multiple) administration.
    [0076] In one embodiment, the dosage is sufficient to decrease the plasma levels of Phe in the patient by 25% or more.
    [0077] In some embodiments, rAAV.hPAH administered in combination with one or more therapies for the treatment of PKU, such as a low Phe diet or the administration of sapropterin dihydrochloride.
    5.4. Measuring Clinical Objectives [0078] Treatment effectiveness measures can be measured by the expression and activity of the transgene, as determined by plasma Phe levels and / or PAH activity. An evaluation
    Petition 870190072015, of 7/29/2019, p. 34/64
    Additional 30/38 effectiveness can be determined by the clinical assessment of food tolerance to copper.
    [0079] As used in this document, the vector rAAV.hPAH in this document functionally replaces or functionally supplements the defective PAH of patients with active PAH when the patient expresses a sufficient level of PAH to achieve PAH activity resulting in Phe levels between 120 -360 pmol / L.
    [0080] The following examples are illustrative only and are not intended to limit the present invention.
    EXAMPLES [0081] The following examples are illustrative only and are not intended to limit the present invention.
    EXAMPLE 1: Phenylketonuria (PKU) Mouse Models [0082] PAH 7- mice were generated by CRISPR / Cas9 technology at Jackson Labs. Cas9 mRNA and two guide RNA (sgRNA) were injected into C57BL / 6 wild-type mice, aiming at the second coding exon of the PAH gene directly in the mice's zygotes. The mice that grew from these embryos were sequenced to determine the mutation (s) and then crossed with C57BL / 6J mice to transmit the allele and confirm transmission of the germline.
    [0083] Four different mutations were generated and the strains of mice were designated as PAH_KO_A, PAH_KO_B, PAHKOC and PAH_KO_D. The PAH_KO_A mice demonstrated a 3 bp substitution followed by a 64 bp deletion from 6534 nt to 6600 nt of the Mus musculus PAH gene [NC-000076.6]. The PAH_KO_B and PAH_KO_C mice showed a single base pair insertion after 6589 nt and 6539 nt respectively. PAH_KO_D showed a 6 bp deletion from 6535 nt to 6540 nt. FIGURE 9 shows an alignment of a portion
    Petition 870190072015, of 7/29/2019, p. 35/64
    31/38 of the PAH sequence for the wild type, PAH_KO_A, PAH_KO_B, PAH_KO_C, PAH_KO_D and consensus. A study of the natural history of these mice was carried out. Blood samples were collected via retro-orbital or submandibular bleeding. Plasma phenylalanine (Phe) levels were detected using LC / MS / MS and data from mice PAH_KO_A, PAH_KO_B and PAH_KO_C were acquired and presented in FIGURES 2A, 3A and 4A, respectively, and summarized in FIGURE 5A. Wild type litter brothers were provided as negative controls. Compared to controls, plasma phenylalanine levels in the PAH_KO_A, PAH_KO_B and PAH_KO_C mice were significantly higher, indicating a functional PAH deficiency in these mice. This also suggested that the PAH_KO_A, PAH_KO_B and PAH_KO_C mice could serve as mouse models for phenylketonuria (PKU) in humans.
    [0084] However, the fourth group of null mice, PAH_KO_D, did not exhibit a high level of plasma phenylalanine and therefore were excluded from further analysis.
    EXAMPLE 2: AAV Vectors Containing hPAHAAV8.TBG.PI.hPAHco.WPRE.bGH.
    [0085] The gene therapy vector AAV8.TBG.PI.hPAHco.WPRE.bGH was constructed by an AAV8 vector containing a codon-optimized human PAH cDNA under the control of TBG, a hybrid promoter based on the binding globulin promoter to human thyroid hormone and microglobin / bicunin stimulator (FIGURE 1). The PAH expression cassette was flanked by inverted terminal repeats derived from AAV2 (ITRs) and the expression was conducted by a hybrid of the TBG enhancer / promoter and the Groundhog Virus Post-transcriptional regulatory element (WPRE) ) as an enhancer.
    Petition 870190072015, of 7/29/2019, p. 36/64
    32/38 transgene also included the Promega SV40 intron misc (PI) and a bovine growth hormone (bGH) polyadenylation signal. The genome sequence of the vector is shown in SEQ ID NO: 20.
    [0086] The vector was prepared using conventional 293 cell triple transfection techniques as described, for example, by Mizukami, Hiroaki et al. A Protocol for AAV vector production and purification. Diss. Di-vision of Genetic Therapeutics, Center for Molecular Medicine, 1998., which is incorporated into this document by reference. All vectors were produced by Vector Core at the University of Pennsylvania as previously described [Lock, M., et al., Hum Gene Ther, 21: 1259-1271 (2010)].
    EXAMPLE 3: Vectors AAV8.hPAH in the PKU Model [0087] All animal procedures were performed according to protocols approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Pennsylvania.
    [0088] Twenty PAH_KO_A mice were generated. Seven males and three females were evaluated in the study of natural history. On Day 56 of the natural history study, 1 x 10 13 GC / kg of the vector AAV8.TBG.PI.hPAHco.WPRE.bGH were injected intravenously into three male mice with Identification Numbers 1531, 1532 and 1533 through the vein of the tail. 1 x 10 12 GC / kg of the vector were injected into four male mice with the Identification Numbers 1538, 1539, 1554 and 1564. 1 x 10 12 GC / kg of the vector were injected into three female mice with the Identification Numbers 1507, 1536 and 1537. Blood samples were collected weekly to assess plasma phenylalanine concentration (FIGURE 2B). A higher level of phenylalanine was detected in PAH_KO_A mice before injection compared to controls in the same litter, indicating a PAH deficiency in PAH_KO_A mice. 7 days after the vector injection, the level of
    Petition 870190072015, of 7/29/2019, p. 37/64
    33/38 phenylalanine in the plasma of PAH_KO_A mice decreased while the controls remained stable. This result demonstrated that a single injection of AAV8.TBG.PI.hPAHco.WPRE.bGH in PAH_KO_A mice can rescue PAH deficiency and reduce the pathological accumulation of phenylalanine in the blood.
    [0089] The effects of gender differences and the two doses of the AAV8.TBG.PI.hPAHco.WPRE.bGH vectors were further evaluated in PAH_KO_A mice (FIGURE 2C). Plasma phenylalanine levels were observed weekly for 11 weeks, for example, as described in Gregory et al., Blood phenylalanine monitoring for dietary compliance among patients with phenylketonuria: comparison of methods, Genetics in Medicine (November 2007) 9, 761- 765, which is incorporated into this document by reference. Two of three female mice received 1 x 10 12 GC / kg of the vectors and all seven males with both doses at 1 x 10 12 GC / kg and 1 x 10 13 GC / kg showed a reduced concentration of phenylalanine in the plasma. The phenylalanine of the seven male mice remained at comparatively low levels during the 11-week observation period, while all three females showed a slow increase in the level of phenylalanine in the plasma.
    [0090] Three female PAH_KO_B mice were generated and examined in a natural history study. Weekly bleeds for phenylalanine levels were performed and the result confirmed an abnormal accumulation of phenylalanine in the blood compared to healthy controls in the same litter. After intravenous injection of 1 x 10 12 GC / kg of AAV8.TBG.PI.hPAHco.WPRE.bGH, a decrease in the level of phenylalanine was observed in the three females and the low level was maintained during the observation period of 8 weeks after injection. [0091] Two PAH_KO_C male mice were generated for
    Petition 870190072015, of 7/29/2019, p. 38/64
    34/38 this study and used in the study of natural history. A weekly collection of blood samples was performed and the concentration of phenylalanine was assessed. The data showed that during the 9 weeks of observation, both PAH_KO_C mice and their siblings from the same heterozygous / wild-type litter maintained a comparatively stable concentration of phenylalanine in the plasma, while the knock-out mice demonstrated a significantly higher level.
    [0092] An additional study of PAH expression and enzymatic activity in PAH 7- injected mice was performed. The livers of the PAH_KO_A, PAH_KO_B and PAH_KO_C mice injected with vectors or PBS are collected, as well as the healthy controls of the same litter. The mRNA is extracted from the liver and the expression of human PAH is evaluated via RT-PCR. To determine PAH protein expression, liver lysates are prepared for western blot detection while liver sections are prepared for immunohistochemistry. Experiments are also carried out to evaluate the PAH enzyme activity of PAH 7- mice treated with the vector, as well as controls.
    [0093] To fully assess the gender difference in all three PAH 7- mice, the PAH_KO_A, PAH_KO_B and PAH_KO_C mice were crossed to assess the plasma concentration of phenylalanine, the expression of PAH at the level of mRNA and protein and enzyme activity of PAH before and after the injection of AAV8.TBG.PI.hPAHco.WPRE.bGH.
    [0094] To determine the dose-dependent expression of AAV8.TBG.PI.hPAHco.WPRE.bGH and the potential toxicity of the highest dose, several doses of AAV8.TBG.PI.hPAHco.WPRE.bGH are injected into PAH mice 7- and an additional assessment of phenylalanine accumulation and PAH expression / activity are performed.
    Petition 870190072015, of 7/29/2019, p. 39/64
    35/38 [0095] Similar experiments were performed with the AAV8.TBG.hPAHco.bGH. PKU B mice aged 17-22 weeks received 10 12 GC / kg from one of AAV8.TBG.hPAHco.bGH or AAV8.TBG.hPAHco.WPRE.bGH (or PBS for control) after pre-phenylalanine levels treatment have been established. The mice were bled weekly and the plasma was isolated and the concentration of phenylalanine was determined (FIGURE 6A). At the end of the study, the liver was collected and the analysis of genomic copy (FIGURE 6B) and immunohistochemistry (FIGURE 6C) was performed. Phenylalanine levels were reduced in mice treated with both AAV8.TBG.hPAHco.bGH and AAV8.TBG.hPAHco.WPRE.bGH.
    [0096] Other studies were carried out with the vector
    AAV8.TBG.hPAHco.bGH. 10 11 GC / kg of AAV8.TBG.hPAHco were injected intravenously into wild type, heterozygous (circle) and PKU_KO_A (KO) mice after baseline phenylalanine levels were established. The mice were then bled weekly and the plasma was isolated and analyzed for Phe concentration. Plasma Phe levels decreased by 71% after intravenous administration of AAV8.TBG.hPAHco. FIGURE 7. [0097] PKU_KO_B mice received 10 12 GC / kg, 3 x 10 11 GC / kg or 10 11 GC / kg of AAV8.TBG.hPAHco after baseline phenylalanine levels were established. The mice were then bled weekly and the plasma was isolated and analyzed for Phe concentration. At the end of the study, livers were collected and the analysis of genomic and immunohistochemical copies was performed. Protein expression and reduction in Phe levels were observed at a dose of 10 12 GC / kg.
    [0098] Meanwhile, administration of 10 12 GC / kg of each of the following vectors, AAV8.TBG.PI.hPAHco.bGH,
    Petition 870190072015, of 7/29/2019, p. 40/64
    36/38
    AAV8.LSP.IVS2.hPAHco.bGH, AAV8.A1AT.hPAHco.BGH,
    AAV8.TTR.hPAHco.BGH, AAV8.TBG.PI.hPAHnativesequence.bGH, AAV8.ABPS.TBG.hFIXintron.hPAHco.BGH, AAV8.ABPS.TBGS1 .hFIXintron.hPAHco.BGH,
    AAV8.ApoE.A1 AT.hFIXintron.hPAHco.BGH, was also performed and served as a comparison.
    [0099] In conclusion, a single injection of the vector AAV8.TBG.PI.hPAHco.WPRE.bGH resulted in a substantial reduction in plasma phenylalanine and concomitant functional correction when administered intravenously in three PAH-deficient mice.
    EXAMPLE 4: AAV Gene Therapy for Phenylketonuria [00100] Phenylketonuria (PKU) is an autosomal recessive genetic disease caused by the attenuation of the activity of phenylalanine-4hydroxylase (PAH), resulting in the accumulation of phenylalanine in tissues and blood. High levels of phenylalanine in the bloodstream are believed to inhibit the transport of other large neutral amino acids across the blood-brain barrier, affecting brain development and resulting in intellectual disability and seizures. Currently, the treatment of PKU is limited to maintaining a restricted diet of phenylalanine and products aimed at stabilizing residual PAH. An AAV gene therapy approach to the liver described in this document serves to improve the current standard of treatment.
    [00101] To investigate the development of gene therapy for PKU, four unique mouse strains were created inducing different mutations in exon 1 of the PAH gene with the CRISPR / Cas9 technology as described in this document. A natural history study was carried out on each of these strains to determine disease progression and identify the strain that best reproduced
    Petition 870190072015, of 7/29/2019, p. 41/64
    37/38 the human PKU phenotype. Both PKU colonies, designated BeC, contained a single base pair (bp) deletion at different locations in exon 1 and maintained mean phenylalanine levels of 2049 μΜ and 1705 μΜ, respectively, compared to normal levels of 70 pM. The PKU colony A, despite having a 64 bp deletion and a 3 bp insertion in exon 1 of the PAH gene, had a modestly higher mean phenylalanine level of 477 pM. Colony D of PKU, which had a deletion of 6 bp, had levels of phenylalanine equivalent to those of the wild type litter brothers. After administration of the AAV8 vector at a dose of 1 x 10 12 GC / kg for the expression of an optimized version of the human codon of PAH in the PKU B mouse colony, plasma phenylalanine levels were reduced by 87% to 222 pM. This reduction in plasma phenylalanine levels restored the males' ability to produce offspring. These results represent the development of an AAV-based therapy for PKU.
    [00102] All publications cited in this report, as well as US Provisional Patent Applications Nos. 62 / 440,651, 62 / 469,898, and 62 / 506,373, are incorporated herein by reference. Likewise, the SEQ ID NOs referred to in this document and which appear in the attached string listing are incorporated by reference. Although the invention has been described with reference to particular embodiments, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to remain within the scope of the appended claims. Sequential Listing in Free Text:
    权利要求:
    Claims (23)
    [1]
    1. Recombinant adenoassociated virus (rAAV) useful as a therapeutic agent for liver-directed phenylketonuria (PKU), characterized by the fact that it comprises an AAV capsid, and a vector genome packaged therein, said vector genome comprising:
    (a) a 5 'AAV inverted terminal repeat (ITR) sequence;
    (b) a promoter;
    (c) a codon-optimized sequence that encodes a human hydroxylase-phenylalanine (PAH);
    (d) a 3 'AAV ITR.
    [2]
    2. rAAV according to claim 1, characterized by the fact that the coding sequence of (c) is SEQ ID NO: 1.
    [3]
    3. rAAV according to claim 1, characterized by the fact that the rAAV capsid is an AAV8 capsid.
    [4]
    4. rAAV according to claim 1, characterized by the fact that the promoter is the TBG promoter or a TBG-
    S.
    [5]
    5. rAAV according to claim 1, characterized by the fact that the promoter is a promoter of Al AT.
    [6]
    6. rAAV according to claim 1, characterized by the fact that the promoter is the promoter of LSP.
    [7]
    7. rAAV according to claim 1, characterized by the fact that the promoter is the TTR promoter.
    [8]
    8. rAAV according to claim 1, characterized in that the ITR of AAV 5 'and / or ITR of AAV3' is AAV2.
    [9]
    9. rAAV according to claim 1, characterized by the fact that the vector genome further comprises a poly A.
    [10]
    10. rAAV according to claim 1, characterized by the fact that poly A is from bGH.
    Petition 870190072015, of 7/29/2019, p. 44/64
    2/3
    [11]
    11. rAAV according to claim 1, characterized by the fact that it also comprises a WPRE.
    [12]
    12. rAAV according to claim 1, characterized by the fact that it further comprises an intron.
    [13]
    13. rAAV according to claim 12, characterized in that the intron is human IVS2 beta globin or SV40.
    [14]
    14. rAAV according to claim 1, characterized by the fact that it also comprises an enhancer.
    [15]
    15. rAAV according to claim 14, characterized by the fact that the enhancer is an APB enhancer, ABPS enhancer, an MIC / Bik alpha enhancer, TTR enhancer, EN34, or ApoE enhancer.
    [16]
    16. rAAV according to claim 1, characterized by the fact that the vector genome is from about 3 kilobases to about 5.5 kilobases in size.
    [17]
    17. Aqueous suspension suitable for administration to a patient with phenylketonuria, said aqueous suspension characterized by the fact that it comprises a suspension of aqueous liquid and about 1 X10 12 GC / mL to about 1 X10 14 GC / mL of an adenoassociated virus recombinant (rAAV) useful as a liver-directed therapy for phenylketonuria, said rAAV having an AAV capsid, and having packed a vector genome comprising:
    (a) a 5 'AAV inverted terminal repeat (ITR) sequence;
    (b) a promoter;
    (c) a coding sequence that codes for a human hydroxylase-phenylalanine (PAH); and (d) a 3 'AAV ITR.
    [18]
    18. Suspension according to claim 17,
    Petition 870190072015, of 7/29/2019, p. 45/64
    3/3 characterized by the fact that the suspension is suitable for intravenous injection.
    [19]
    19. Suspension according to claim 17, characterized in that the suspension further comprises a surfactant, preservative, and / or buffer dissolved in the aqueous liquid suspension.
    [20]
    20. Method of treating a patient having phenylketonuria with an rAAV as defined in claim 1, characterized by the fact that the rAAV is delivered from about 1 x 10 10 to about 1 x 10 15 genome copies (GC) / kg in an aqueous suspension, in which the GC is calculated as determined based on oqPCR or ddPCR.
    [21]
    21. rAAV according to claim 1, characterized by the fact that the vector genome comprises SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24 or SEQ ID NO: 25.
    [22]
    22. Suspension according to claim 17, characterized by the fact that the rAAV capsid is an AAV8 capsid.
    [23]
    23. Use of an rAAV as defined in any of claims 1 to 16, characterized by the fact that it is for the treatment of phenylketonuria, in a subject in need of it.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112019013576A2|2020-02-04|gene therapy for the treatment of phenylketonuria
    JP2021087431A|2021-06-10|Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
    KR20160026841A|2016-03-09|Vectors comprising stuffer/filler polynucleotide sequences and methods of use
    JP2018537984A|2018-12-27|Adeno-related viral vectors useful in the treatment of spinal muscular atrophy
    AU2017215211A1|2018-08-09|Gene therapy for treating mucopolysaccharidosis type i
    JP2022513034A|2022-02-07|Gene therapy for neuronal ceroid lipofuscinosis
    JP2020514286A|2020-05-21|Gene therapy to treat Wilson's disease
    CN114127275A|2022-03-01|Composition for treating pompe disease
    JP2019505183A|2019-02-28|Composition for the treatment of Krigler-Najjar syndrome
    TW201919676A|2019-06-01|Gene therapy for treating mucopolysaccharidosis type II
    TW202045728A|2020-12-16|Compositions useful in treatment of krabbe disease
    JP2020506705A|2020-03-05|Gene therapy to treat citrullinemia
    IL281923D0|2021-05-31|Compositions useful for treating gm1 gangliosidosis
    JP7037574B2|2022-03-16|Composition useful for the treatment of spinal muscular atrophy
    TW202140781A|2021-11-01|Compositions useful for treating gm1 gangliosidosis
    WO2021231443A1|2021-11-18|Compositions useful in treatment of krabbe disease
    WO2021202532A1|2021-10-07|Gene therapy for treating propionic acidemia
    Foust et al.2017|Gene Transfer in Spinal Muscular Atrophy
    CN113574176A|2021-10-29|Delivery of CLN6 polynucleotides by adeno-associated viruses
    同族专利:
    公开号 | 公开日
    CA3048038A1|2018-07-05|
    CN110325199A|2019-10-11|
    US20190336550A1|2019-11-07|
    EP3562494A1|2019-11-06|
    JP2020504619A|2020-02-13|
    KR20190100318A|2019-08-28|
    EP3562494A4|2020-08-19|
    MX2019007876A|2019-10-15|
    WO2018126112A1|2018-07-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DK1453547T3|2001-12-17|2016-12-05|Univ Pennsylvania|ADENOASSOCATED VIRUS SEROTYPE 8 SEQUENCES, VECTORS CONTAINING THESE AND APPLICATIONS THEREOF|
    US20040142416A1|2002-04-30|2004-07-22|Laipis Philip J.|Treatment for phenylketonuria|
    AU2013243955B2|2012-04-02|2018-02-22|Modernatx, Inc.|Modified polynucleotides for the production of oncology-related proteins and peptides|
    WO2014151341A1|2013-03-15|2014-09-25|The Trustees Of The University Of Pennsylvania|Compositions and methods for treating mpsi|
    EA201992208A1|2013-10-22|2020-07-31|Транслейт Био, Инк.|TREATMENT OF PHENYLKETONURIA USING mRNA|
    MX2016011686A|2014-03-09|2016-11-07|Univ Pennsylvania|Compositions useful in treatment of ornithine transcarbamylase deficiency.|WO2010045659A1|2008-10-17|2010-04-22|American Gene Technologies International Inc.|Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules|
    US10137144B2|2016-01-15|2018-11-27|American Gene Technologies International Inc.|Methods and compositions for the activation of gamma-delta T-cells|
    JP2019501661A|2016-01-15|2019-01-24|アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド|Methods and compositions for activation of gamma delta T cells|
    JP2019509029A|2016-02-08|2019-04-04|アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド|HIV vaccination and immunotherapy|
    EP3426777B1|2016-03-09|2022-02-16|American Gene Technologies International Inc.|Combination vectors and methods for treating cancer|
    WO2018009246A1|2016-07-08|2018-01-11|American Gene Technologies International Inc.|Hiv pre-immunization and immunotherapy|
    KR20200127187A|2018-02-01|2020-11-10|호몰로지 메디슨, 인크.|Adeno-associated virus composition for PAH gene delivery and method of use thereof|
    US10610606B2|2018-02-01|2020-04-07|Homology Medicines, Inc.|Adeno-associated virus compositions for PAH gene transfer and methods of use thereof|
    AU2019265560A1|2018-05-09|2020-11-26|Biomarin Pharmaceutical Inc.|Methods of treating phenylketonuria|
    KR20210076051A|2018-10-12|2021-06-23|젠자임 코포레이션|Generation of improved human PAH for the treatment of severe PKU by liver-specific gene replacement therapy|
    CN113874508A|2019-03-13|2021-12-31|世代生物公司|Non-viral DNA vectors and their use for expressing phenylalanine hydroxylasetherapeutics|
    CA3137698A1|2019-05-31|2020-12-03|Tyler LAHUSEN|Optimized phenylalanine hydroxylase expression|
    WO2021146260A1|2020-01-13|2021-07-22|Homology Medicines, Inc.|Methods of treating phenylketonuria|
    WO2021144649A2|2020-01-16|2021-07-22|Takeda Pharmaceutical Company Limited|Adeno associated virus based gene therapy for phenylketonuria|
    WO2021202943A1|2020-04-03|2021-10-07|Biomarin Pharmaceutical, Inc.|Treatment of phenylketonuria with aav and therapeutic formulations|
    WO2021252952A1|2020-06-11|2021-12-16|Sangamo Therapeutics, Inc.|Methods and compositions for expressing phenylalanine hydroxylase|
    CN113265424A|2021-05-14|2021-08-17|华中科技大学同济医学院附属协和医院|Recombinant adeno-associated virus vector for treating atherosclerosis, genome composition and application|
    法律状态:
    2021-10-13| B350| Update of information on the portal [chapter 15.35 patent gazette]|
    优先权:
    申请号 | 申请日 | 专利标题
    US201662440651P| true| 2016-12-30|2016-12-30|
    US201762469898P| true| 2017-03-10|2017-03-10|
    US201762505373P| true| 2017-05-12|2017-05-12|
    PCT/US2017/068897|WO2018126112A1|2016-12-30|2017-12-29|Gene therapy for treating phenylketonuria|
    [返回顶部]